EMEA-002798-PIP02-21 - paediatric investigation plan

Retifanlimab

Key facts

• Active Substance:
  Retifanlimab
• Therapeutic area:
  Oncology
• Decision number:
  P/0139/2022
• PIP number:
  EMEA-002798-PIP02-21
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of endometrial carcinoma
• Route(s) of administration:
  All routes of administration
• Contact for public enquiries:

  Incyte Biosciences Distribution B.V.

  [e-mail]

  [phone]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  13/04/2022

Decision

P/0139/2022 : EMA decision of 13 April 2022 on the granting of a product-specific waiver for retifanlimab (EMEA-002798-PIP02-21)

AdoptedReference Number: EMA/157576/2022